Disc Medicine (NASDAQ:IRON) Price Target Increased to $43.00 by Analysts at Raymond James

Disc Medicine (NASDAQ:IRON - Get Free Report) had its price objective raised by equities researchers at Raymond James from $40.00 to $43.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Raymond James' target price would suggest a potential upside of 41.63% from the company's current price.

Other research analysts have also issued research reports about the stock. Wedbush reiterated an "outperform" rating and issued a $43.00 price target (down previously from $84.00) on shares of Disc Medicine in a research note on Monday, April 1st. Stifel Nicolaus upped their price objective on Disc Medicine from $71.00 to $73.00 and gave the company a "buy" rating in a report on Monday, April 8th. BMO Capital Markets dropped their target price on Disc Medicine from $80.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, April 2nd. Morgan Stanley reduced their target price on shares of Disc Medicine from $75.00 to $40.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 2nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Disc Medicine in a research note on Monday, April 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $57.71.

Disc Medicine Stock Performance

Disc Medicine stock traded down $0.41 during midday trading on Friday, reaching $30.36. 196,829 shares of the company's stock were exchanged, compared to its average volume of 408,688. The stock's 50-day simple moving average is $44.43 and its 200 day simple moving average is $53.56. The firm has a market cap of $732.89 million, a price-to-earnings ratio of -8.70 and a beta of 0.44. Disc Medicine has a 52 week low of $25.60 and a 52 week high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, March 21st. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.22). Research analysts forecast that Disc Medicine will post -4.44 earnings per share for the current year.

Insiders Place Their Bets

In other Disc Medicine news, Director William Richard White sold 2,560 shares of the company's stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $31.80, for a total transaction of $81,408.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.71% of the company's stock.

Institutional Trading of Disc Medicine

Hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in shares of Disc Medicine in the third quarter valued at approximately $28,000. AJOVista LLC acquired a new position in Disc Medicine in the 4th quarter valued at approximately $63,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Disc Medicine during the fourth quarter valued at $161,000. ProShare Advisors LLC acquired a new position in shares of Disc Medicine during the first quarter worth $211,000. Finally, Bleakley Financial Group LLC bought a new stake in shares of Disc Medicine in the fourth quarter worth $215,000. Institutional investors and hedge funds own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.